- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04615845
A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
Une étude ouverte, monocentrique, de phase 1 pour évaluer l'innocuité de l'immunothérapie anticancéreuse avec des cellules dendritiques autologues chez les patients atteints d'un cancer de la prostate métastatique résistant à la castration (mCRPC)
The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Cellgram-DC-PC is an autologous dendritic cell-based cancer immunotherapy developed for patients with metastatic castration-resistant prostate cancer (mCRPC). This was a Phase 1, single-center, open-label clinical trial designed to characterize the safety profile of Cellgram-DC-PC following administration in patients with mCRPC.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
-
Seoul, Corée du Sud
- Asan medical center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
19 and under 80 years
-
Histologically confirmed prostate adenocarcinoma
-
Patients with stage M1a or M1b with extrapelvic lymph nodes and bone metastases
-
Patients diagnosed with castration-resistant prostate cancer after failure of male hormone deprivation therapy (Castrate levels of testosterone <50 ng/dL) and If either a or b is satisfied:
- Biochemical progression: Prostate Specific Antigen (PSA) increases three times in a row at 1 week intervals, two 50% increases compared to the lowest point, PSA> 2ng/mL, or
- Radiological progression: appearance of new lesions; 2 or more new lesions on the bone scan
-
Asymptomatic or mild patients after previous treatment
- Patients who have not used narcotic analgesics within 21 days prior to enrollment
- Patients with an average weekly pain of less than 4 on the Visual Analogue Scale(VAS) (out of 10)
-
Combination of Luteinizing hormone-releasing hormone(LHRH) analogs (leuprolide (Lupron, Viadur, Eligard) and goserelin (Zoladex, etc.) for the inhibition of gonadotropin is allowed
-
Whole body performance status: European Cooperative Oncology Group(ECOG) 0~1
-
Patients whose life expectancy is at least 6 months or longer
-
Hb ≥ 8.0g/dL, Absolute Neutrophil Count(ANC) ≥ 1,500/mm3, Platelets ≥ 100,000/mm3
-
Serum Creatinine ≤ 2.0 x Upper Limit of Normal(ULN) or Calculated Creatinine Clearance > 30mL/min
-
Total Bilirubin ≤ 1.5 x ULN or Direct bilirubin ≤ ULN, Aminotransferase (AST)/Alanine aminotransferase(ALT) <2.5 x ULN
-
Patients who did not receive surgery, radiation therapy, or immunotherapy within the last 6 weeks and recovered from side effects
-
Patients who agreed to use medically recognized contraceptive methods during the clinical trial participation period
-
Patients who voluntarily participated in clinical trials and signed the Informed Contents Form (ICF)
Exclusion Criteria:
- Patients who have a local recurrence and are scheduled for local treatment.
- Patients with malignant tumors other than non-melanoma skin cancer in the past 3 years
- Patients with visceral metastases (metastases to the lungs, liver, adrenal glands, peritoneum, brain, etc.)
- Patients who previously received anti-tumor immunotherapy (anti-PD1, anti-PDL1 or anti-PDL2, etc.) or participated in immunotherapy-related clinical trials
- Patients with active autoimmune diseases requiring systemic immunosuppression treatment (e.g., immunosuppressants such as cyclosporin A or azathioprine or steroids for disease control)
- Patients with medical conditions requiring continuous or intermittent administration of systemic steroids or immunosuppressants
- Patients who received blood products (limited to whole blood products) within 4 weeks of screening criteria, or patients who received colony stimulating factors (Colony Stimulating Factor or recombinant Erythropoietin)
- Patients with a history of organ or hematopoietic stem cell transplantation
- Patients with acute or chronic infections requiring systemic treatment
- Patients known to be infected with human immunodeficiency virus (HIV)/serum positive
- Patients with active hepatitis A, B or C
- Patients with untreated syphilis (Fluorescent Treponemal Antibody Absorption Test (FTA-ABS) Immunoglobulin M positive patients)
- Patients expected to require therapeutic biotherapy or immunotherapy
- Patients who received live virus vaccines (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, Bacillus Calmette-Guerin (BCG), oral typhoid vaccine, Flu-Mist, etc.) within 30 days
- Patients with a history of anaphylaxis to gentamicin
- Others, if the person in charge of the study determines that it is not suitable for the clinical trial
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cellgram-DC-PC
Participants received Cellgram-DC-PC by subcutaneous injection near the inguinal lymph nodes. |
Patients received three subcutaneous injections of Cellgram-DC-PC (autologous dendritic cells) near the inguinal lymph nodes at Weeks 0, 2, and 4.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse Event
Délai: From informed consent to the end of treatment at Week 28.
|
Adverse events (AEs) were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
From informed consent to the end of treatment at Week 28.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Immune Response
Délai: At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
Tumor antigen-specific immune responses were evaluated by measuring changes in serum IFN-γ and IL-12 levels and antigen-specific T-cell responses following administration of the investigational product. |
At baseline (Week 0), Week 4, Week 8, Week 16, and Week 28.
|
|
Change in Prostate-Specific Antigen (PSA)
Délai: At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Exploratory efficacy was evaluated by measuring changes in prostate-specific antigen (PSA) levels from pre-treatment (Week 0) to post-treatment assessment. |
At baseline (Week 0), Week 2, Week 4, Week 8, Week 16, and Week 28.
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: BUMJIN LIM, Ph.D, Asan Medical Center
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PMC-DC-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be made available to other researchers.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .